. Author manuscript; available in PMC: 2011 Aug 15.

Published in final edited form as: Bioorg Med Chem. 2010 Jun 22;18(16):6099–6108. doi: 10.1016/j.bmc.2010.06.053

Table 1.

Translated sequences of variable inserts, occurrence frequency, and β-galactosidase activities of SICLOPPS leads selected as antagonists of Hdm2–p53 and Hdmx–p53 interactions.

Target interaction	SICLOPPS Isolate (# of occurrences)	Sequence in linear form	% derepression (Hdm2)^a	% derepression (Hdmx)^a
Hdm2–p53	I-1 (2)	CLWWYM	18 ± 2	41 ± 4
	II-1 (1)	CIWWYM	12 ± 2	49 ± 3
	II-7 (1)	CIFYYV	51 ± 5	42 ± 3
	IV-7 (1)	CMFYYI	18 ± 3	37 ± 3
Hdmx–p53	X1-25 (1)	CLFFNY	18 ± 2	47 ± 2
	X2-1 (1)	CKAVLF	7 ± 3	51 ± 3
	X4-40 (1)	CHLRWL	10 ± 3	58 ± 4
	X4-46 (1)	CDLRWF	6 ± 2	76 ± 4
	X6-19 (1)	CRLLDF	7 ± 2	49 ± 3

% derepression is determined as the percentage of β–galactosidase activity enhancement in the selected SICLOPPS strain versus that in the unrepressed control (see Table S2 for details).